Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966622 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL10404578 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL2133320 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL4393614 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| Lithium Ion SCHEMBL1457619 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL26227 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL25283 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| Potassium Ion SCHEMBL5250865 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL20484784 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL11433030 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118599275-B | Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging | 东莞市万塑成塑料有限公司 | 2025-02-11 | — | — | CN | claimed |
| EP-1912683-B1 | ANTIMICROBIAL COMPOSITION | ETHICON INC (US) | 2014-03-12 | — | — | EP | claimed |
| CN-118599275-B | Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging | 东莞市万塑成塑料有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118599275-A | Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging | 东莞市万塑成塑料有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-11801262-B2 | Antibiotic compositions | THIOREDOXIN SYSTEMS AB (SE) | 2023-10-31 | — | — | US | disclosed |
| US-20230152311-A1 | Analyte Test Strip Assays, and Test Strips and Kits for Use in Practicing the Same | BECTON, DICKINSON AND COMPANY | 2023-05-18 | — | — | US | disclosed |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3548043-B1 | ANTIBIOTIC COMPOSITIONS COMPRISING SILVER IONS AND EBSELEN | THIOREDOXIN SYSTEMS AB (SE) | 2022-10-05 | — | — | EP | disclosed |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200281967-A1 | Antibiotic Compositions | THIOREDOXIN SYSTEMS AB (SE) | 2020-09-10 | — | — | US | disclosed |
| US-10653717-B2 | Antibiotic compositions | THIOREDOXIN SYSTEMS AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-20040208908-A1 | Antimicrobial medical articles containing a synergistic combination of anti-infective compounds and octoxyglycerin | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-10-21 | — | — | US | disclosed |
| EP-1363679-A1 | COMBINATIONS OF ANTISEPTIC AND ANTIBIOTIC AGENTS CONTAINING MEDICAL DEVICES | The Trustees of Columbia University in the City of New York (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6582719-B2 | Combinations of antiseptic and antibiotic agents that inhibit the development of resistant microorganisms | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2003-06-24 | — | — | US | disclosed |
| WO-2003000303-A1 | COMBINATIONS OF ANTISEPTIC AND ANTIBIOTIC AGENTS CONTAINING MEDICAL DEVICES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020173775-A1 | Combinations of antiseptic and antibiotic agents that inhibit the development of resistant microorganisms | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2002-11-21 | — | — | US | disclosed |
| EP-1165155-A1 | TRICLOSAN AND SILVER COMPOUND CONTAINING MEDICAL DEVICES | The Trustees of Columbia University in the City of New York (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010010016-A1 | Triclosan and silver compound containing medical devices | THE TRUSTEE OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2001-07-26 | — | — | US | disclosed |
| US-6224579-B1 | PREVENTING OR INHIBITING INFECTION WHILE AVOIDING UNDESIRABLE ADVERSE REACTIONS TO CHLORHEXIDINE; CATHETERS ARE SMOOTHER AND SHINIER; NO BACTERIAL ADHERENCE; LESS PHYSICALLY IRRITATING | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2001-05-01 | — | — | US | disclosed |
| WO-2000057933-A1 | TRICLOSAN AND SILVER COMPOUND CONTAINING MEDICAL DEVICES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | CD47, IFNG, TLR9 | KDM4E 4290/4885ALDH1A1 3552/4885HPGD 4222/4885 |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | KDM4E 2640/4885ALDH1A1 1357/4885HPGD 3242/4885 |
| US-20200281967-A1 | Antibiotic Compositions | MRPL21, RPS5, MRPS35 | KDM4E 3518/4885ALDH1A1 2846/4885HPGD 2898/4885 |
| US-10653717-B2 | Antibiotic compositions | MRPL21, RPS5, MRPS35 | KDM4E 3518/4885ALDH1A1 2846/4885HPGD 2898/4885 |
| US-11801262-B2 | Antibiotic compositions | MRPL21, RPS5, MRPS35 | KDM4E 3518/4885ALDH1A1 2846/4885HPGD 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.